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1. Introduction 
Human immunodeficiency virus (HIV) infection can involve various organs of the body. 
Kidney involvement is frequently seen during course of human immunodeficiency virus 
infection and it has become fourth leading condition contributing to death in acquired 
immunodeficiency virus (AIDS) patients after sepsis, pneumonia, and liver disease. Rao first 
described the presence of focal segmental glomerulosclerosis and renal failure with HIV 
infection in 1984. This entity is now known as HIV-associated nephropathy (HIVAN). Renal 
involvement in HIV infection can manifest in a variety of clinical presentations. Renal 
manifestations can range from acute kidney injury to chronic kidney disease to end stage 
kidney disease. Various fluid and electrolyte disorders and acid base disturbances can also 
occur.  Immune complex mediated glomerular involvement is also seen in these patients 
(see Table).  HIVAN remains the most common form of kidney disease among HIV infected 
individuals which is usually associated with nephrotic range proteinuria. Treatment for 
HIVAN includes use of highly active anti-retroviral therapy (HAART), Angiotensin 
converting enzyme inhibitors and systemic steroid administration. End stage renal disease 
(ESRD) is common in HIV infected individuals and accounts for 1% of patients receiving 
dialysis in USA. Survival of ESRD patients with HIV disease has improved dramatically 
over last one decade due to use of HAART. Both hemodialysis and peritoneal dialysis can be 
dialysis options for ESRD patients due to HIV disease. One year survival rate of HIV 
infected patients is equivalent to that of general population. Renal transplantation recently 
has become a viable option for renal replacement therapy in patients with well controlled 
HIV disease. 
Renal involvement can occur at all stages of HIV infection and can be initial clue to the 
presence of HIV infection in an undiagnosed patient. Renal involvement in HIV disease can 
also occur due to other causes seen in non –HIV infected population like exposure to 
nephrotoxic medications, hemodynamic changes during an acute illness, and obstruction. 
Treatment of HIV infection with highly active anti-retroviral agents itself can induce various 
renal abnormalities. Therefore, evaluation of renal abnormalities should be part of the 
comprehensive work up of a patient with newly diagnosed HIV infection and it should be 
periodically ruled out on subsequent follow up. Usually urinalysis, random protein to 
creatinine ratio, and comprehensive metabolic panel should be obtained as part of the initial 
work up.  Patients on HAART should be monitored for potential renal toxicity of these agents.  
This chapter reviews details of various renal manifestations of HIV disease with special 
focus on presence of chronic kidney disease, pathogenesis and treatment of HIVAN, and 
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renal toxicity associated with use of HAART. Various options of renal replacement therapy 
including renal transplantion will also be discussed.  
 
Acute kidney injury Pre-renal azotemia 
Renal due to Acute tubular toxicity 
Acute interstitial nephritis 
Glomerulonephritis 
Vasculitis 
HUS/TTP 
Obstruction due to crystalluria, stones, 
papillary necrosis, BPH, and urethral 
strictures 
Chronic kidney disease HIVAN 
Can present as proteinuria only with or 
without renal failure. Degree of kidney 
disease can vary from stage 1-5. MDRD 
equation can be used to estimate eGFR. 
 
CKD related to other co morbid conditions 
like Hypertension, Diabetes Mellitus, or due 
to use of recreational drug use like cocaine 
and heroin. 
End Stage Kidney Disease Options for renal replacement therapy 
Disorders of Potassium Hyperkalemia or Hypokalemia 
Disorders of Sodium and Osmolality Hyponatremia and Hypernatremia 
Syndrome of inappropriate ADH secretion 
Disorders of Calcium  Hypocalcemia and Hypercalcemia 
Disorders of Magnesium Hypomagnesemia 
Disorders of Phosphate  Hypophosphatemia or Hyperphosphatemia 
Disorders of acid-base disturbances High anion gap metabolic acidosis  
Non anion gap metabolic acidosis 
Immune complex mediated 
Glomerulonephritis 
Membranoproliferative GN 
Membranous Nephropathy 
Minimal Change Disease 
SLE like GN 
Post infectious GN 
Renal toxicity of HAART Fanconi’s syndrome 
Renal failure 
Diabetes insipidus 
Lactic acidosis 
Table 1. Renal Manifestations of HIV 
2. Acute Kidney Injury 
Acute kidney injury (AKI) is abrupt impairment of renal function and is commonly seen in 
patients infected with HIV both in inpatient and outpatient settings. In era prior to HAART, 
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AKI was commonly due to opportunistic infections and heralded a poor outcome in 
hospitalized patients. The incidence of AKI defined as peak serum creatinine level of 
≥2mg/dl was reported to be 20%.  
An increased risk of inpatient AKI among HIV infected individuals has been reported in the 
modern era of highly active antiretroviral therapy (HAART). One study reported incidence 
of AKI in hospitalized patients with HIV to be 6% as compared with 2.7% in HIV uninfected 
patients. In a large population of hospitalized HIV-infected patients, incidence of 
cardiovascular disease and heart failure increased linearly with severity of AKI. Among HIV 
patients requiring dialysis for AKI, the risk for cardiovascular disease and heart failure were 
1.96 and 4.20 fold greater than individuals who did not develop AKI during their 
hospitalization. The development of AKI in these patients is associated with high mortality 
rate. AKI is also seen in ambulatory HIV infected patients and its incidence has been 
reported to be 5.9/100 person years.  
2.1 Causes of AKI 
No study has assessed etiology of AKI in hospitalized HIV infected patients. The usual 
causes of AKI are commonly encountered in HIV infected individuals as in other 
hospitalized non- HIV infected patients (Table 1).  
The causes of AKI can be divided into prerenal, renal, and post renal causes. Pre-renal 
azotemia and acute tubular necrosis (ATN) remain most common cause of AKI in HIV 
infected individuals (38% and 35% respectively). Patients with AIDS are at high risk of 
prerenal azotemia which results from vomiting, fever, and poor po intake due to underlying 
illness. ATN results from sepsis causing ischemic ATN in up to 50% of cases. Use of 
nephrotoxic agents like aminoglycosides, amphotericin, pentamidine, and intravenous 
administration of contrast agent can cause ATN in 25% of cases.  
Acute interstitial nephritis can result from hypersensitivity reaction to use of certain 
medications or can be caused by certain infections in AIDS patients. Infections associated 
with interstitial disease in immunocompromised patients include cytomegalovirus, candida, 
tuberculosis, and histoplasmosis. Common medications associated with acute interstitial 
nephritis are penicillins, cephalosporins, macrolides, ciprofloxacin, cotrimoxazole, rifampin, 
and nonsteroidal anti-inflammatory drugs. Acute interstitial nephritis secondary to use of 
HAART is very rare. One study found 2/60 biopsy specimens had drug related interstitial 
nephritis. Cessation of offending agent usually leads to renal recovery. Sometimes a short 
course of corticosteroids may need to be given in patients with severe acute interstitial 
nephritis where withdrawl of offending agent fails to improve kidney function. 
Vacular causes of AKI include hemolytic uremic syndrome/thrombotic thrombocytopenic 
purpura can be encountered in HIV seropositive patients. The clinical manifestations are 
similar to that seen in HIV seronegative patients. Laboratory examination reveals 
microangiopathic hemolytic anemia, thrombocytopenia, and impaired kidney function. 
Kidney biopsy reveals platelet and fibrin thrombi in renal and glomerular capillaries. 
Treatment with plasmaphresis and fresh frozen plasma replacement may be effective. 
Obstruction should be considered in differential diagnosis of AKI among HIV infected 
patients. Certain drugs are associated with obstructive nephropathy. These include 
sulfadiazine, acyclovir, atazanavir, and indinavir. Volume depletion with sluggish urine 
flow is the most important risk factor allowing crystallization. Reduced glomerular filtration 
rate is also a risk factor for crystallization. Normal dosing of drugs in patients with reduced 
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GFR is associated with high urinary concentration of insoluble drug and pH of urine. 
Sulfadiazine can cause intratubular obstruction by causing crystal formation. It can also 
cause stone formation which may give rise to ureteral obstruction. Acyclovir can cause 
crystalluria and AKI especially when given intravenously rapidly without concomitant 
hydration. Protease inhibitor indinavir has been reported to cause crystalluria in 20% of the 
patients receiving indinavir at normal dose. The use of this medication has declined 
significantly and has been replaced by less nephrotoxic protease inhibitors. Atazanavir can 
cause nephrolithiasis in up to 0.97% of the individuals taking the drug. Atazanavir stones 
appear to form in alkaline urine. No risk factors have been associated with stone formation 
from atazanavir use. One should keep in mind possibility of atazanavir stones in HIV 
patient who develops renal colic. Ciprofloxacin associated crystal formation commonly 
occurs in HIV infected patients and should be considered as cause of AKI in patients taking 
this antibiotic. Ciprofloxacin induced nephropathy occurs usually in patients with reduced 
renal function with hypovolemia and having urine pH above 6.0. One should adjust dose of 
ciprofloxacin in patients with reduced renal function and urine alkalinization should be 
avoided. Treatment of obstructive nephropathy secondary to crystalluria requires 
discontinuation of offending agent, intravenous hydration, and close monitoring of renal 
function.  
Treatment of AKI in HIV positive individuals is similar to HIV seronegative individuals 
with renal failure. Indications of renal replacement therapy remain the same for both groups 
of patients.  
3. Chronic Kidney Disease 
Chronic kidney disease (CKD) is an important complication of HIV infection. The 
prevalence of impaired renal function defined as estimated glomerular filtration rate (eGFR) 
of <60ml/min/ 1.73m2 varies from 2.4 to 10% depending upon the social and demographic 
characteristics of the studied population. 10-30% of HIV- infected individuals have 
microalbuminuria or proteinuria. A variety of renal abnormalities on renal biopsy have been 
described in these patients. These abnormalities seen on renal biopsy can be HIV associated 
Nephropathy (HIVAN), HIV associated immune complex kidney disease (HIVICK), non 
collapsing focal and segmental glomerulosclerosis, thrombotic microangiopathy, 
nephropathy secondary to use of HAART, and diseases related to common comorbidities 
such as amyloidosis, diabetic nephropathy, hypertensive renal disease etc can be seen on 
renal biopsy.  
HIV infected individuals with glomerular disease present clinically with significant 
proteinuria, hematuria, or reduced kidney function.  Work up should focus on work up for 
possible secondary causes of glomerular diseases along with good history and physical 
examination. The work up should focus on evidence of hepatitis B or C infection, syphilis, 
evidence of malignancy or collagen vascular disease. A kidney biopsy is usually indicated in 
for tissue diagnosis and future management of the disease. 
3.1 Epidemiology 
HIVAN is a histopathological diagnosis based on kidney biopsy only. The true prevalence 
of HIVAN is unknown as many patients with HIV infection do not undergo renal biopsy 
routinely in clinical practice. In kidney biopsy series among HIV infected individuals; 
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HIVAN is seen in 40-60% of renal biopsy specimens.  Autopsy studies on organs from HIV 
infected persons have reported prevalence of HIVAN to be 6.9%. HIVAN is the most 
important cause of milder forms of kidney disease in South Africa where it is commonly 
manifested clinically by microalbuminuria. Infectious Diseases Society of America (IDSA) 
guideline recommends urinalysis and estimation of kidney function for all HIV-infected 
persons at the time of HIV diagnosis. 
HIVAN commonly occurs in African American individuals. With 90% of cases of HIVAN 
occuring in African Americans. The remaining 10% of cases are observed in mixed heritage 
or Hispanic patients. This entity is rarely seen in HIV seropositive white patients. HIVAN 
progresses very fast in African Americans and risk of End Stage Renal Disease (ESRD) is 
similar to diabetes in African American patients with HIVAN. In Caucasians, the risk of 
ESRD associated with HIV is not increased.  
3.2 Pathogenesis 
HIV is pathogenic through direct infection of epithelial cells of the nephron including the 
glomerulus, the tubules and the collecting duct. In situ hybridization studies have found the 
HIV genome in the tubular and glomerular epithelial cells in patients with HIVAN.  The 
pattern of epithelial cell infection determines histological abnormalities seen with HIVAN.  
Transgenic mice expressing a replication-defective HIV-1 construct develop proteinuria, 
reduced renal function, and histologically characteristic HIVAN. Reciprocal transplantation 
studies using this mouse model demonstrate that HIVAN develops only in kidneys 
expressing the transgene. HIV RNA and DNA have been detected in podocytes and renal 
tubular epithelial cells of patients with HIVAN. The mechanism of entry of HIV into renal 
epithelial cells is unknown. Studies have shown that renal epithelial cell is able to support a 
productive viral life cycle, and renal epithelium is an important reservoir for HIV infection. 
Despite undetectable viral load in the serum, HIV can still be present in renal epithelial cells 
where it may undergo rapid replication. This may produce HIV stains in the kidney 
microenvironment that differ from HIV circulating in the blood. 
3.3 Clinical features 
Patients with HIVAN typically present with proteinuria. This proteinuria is variable in 
magnitude, usually is heavy in nephrotic range (>3gm/day), but can be mild and sometimes 
present only as microalbuminuria. HIVAN is associated with rapidly deteriorating renal 
function with high rate of progression to ESRD. These patients usually have poorly 
controlled HIV infection characterized by low CD4 count and high HIV RNA load. Besides 
heavy proteinuria, many patients with HIVAN do not exhibit significant edema or 
Hypertension.  A recent study noted that 43% of patients with biopsy proven HIVAN did 
not have Hypertension. The serum albumin levels remain above 3 gm/dl besides heavy 
proteinuria.  On the contrary, patients with early HIVAN lesions may have normal renal 
function, microalbuminuria or mild proteinuria. Renal function may remain stable for many 
years in these patients. Urinalysis usually shows bland sediment with varying number of 
proteinaceous casts, oval fat bodies, and renal tubular epithelial cells. Abdominal 
ultrasound reveals relatively large, echogenic kidneys. Ultrasound findings are limited 
predictive value. Serologic markers are usually negative in these patients on work up.  A 
diagnostic renal biopsy is usually indicated for diagnosis. 
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3.4 Histopathology 
HIVAN is associated with characteristic glomerular, tubulointerstitial, and electron 
micrographic lesions. The characteristic findings on histopathology include presence of focal 
segmental glomerulosclerosis, cystic tubular dilatation, interstitial edema, cellular infiltrates, 
and dilated tubules filled with pale staining amorphous casts. Collapsing glomerulosclerosis 
is a common variant in patients with HIVAN due to hypercellularity of the cells lining the 
Bowman’s capsule. Proliferation of tubular epithelial cells contributes to micro cyst 
formation and may account for the bigger size of the kidneys. Increased proliferation of 
podocytes is also present and plays an important role in lesions of collapsing FSGS found in 
HIVAN. Immunoflorescence staining is non specific. Electron microscopy reveals 
tubuloreticular inclusions in the endothelial cells of glomerular capillaries. Collapsing FSGS 
is not pathognomonic of HIVAN and can be seen in non- HIV related collapsing focal 
segmental glomerulosclerosis, heroin nephropathy, and as complication of bisphosphonate 
therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Collapsing FSGS 
It shows collapsing focal segmental glomerulosclerosis in a patient with HIV showing global 
collapse of the glomerular capillary loops and proliferation of visceral epithelial cells. 
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Fig. 2. Collapsing FSGS 
It shows podocyte hypertrophy. 
 
 
Fig. 3. Tubulointerstitial involvement in HIV associated Nephropathy 
It shows microcystic dilatation of tubules, proteinaceous material casts within tubular 
lumina, and interstitial inflammation. 
www.intechopen.com
 HIV-Infection – Impact, Awareness and Social Implications of Living with HIV/AIDS 
 
98
 
Fig. 4. Non-Collapsing FSGS  
It shows focal segmental glomerulosclerosis at 12 o’clock position in an HIV infected  
patient. 
3.5 Treatment 
There have been no randomized controlled trials with any type of therapy in treatment of 
HIVAN. US department of Health and Human Services recommends use of HAART for 
diagnosis of HIVAN regardless of CD4 count. Other medications used in the treatment of 
HIVAN in patients with suboptimal response to HAART include angiotensin converting 
enzyme inhibitors and corticosteroids. A summary of the trials conducted in HIVAN is 
given in Table 2. 
3.5.1 Highly Active Antiretroviral Agents (HAART) 
The use of antiretroviral agents has slowed down progression of HIVAN to ESRD and 
reports of patients dependent on dialysis becoming dialysis free have been published after 
use of HAART. In one study, a patient with HIVAN and dialysis dependent renal failure 
became dialysis free after 15 weeks of HAART. Repeat renal biopsy revealed significant 
histologic recovery from fibrosis and infrequent collapsing glomerulosclerosis. 
The rationale for using HAART is based on the direct role of the HIV virus itself in the 
pathogenesis of HIVAN. The effect of HAART on kidney disease progression has been 
characterized by observational studies. The evidence for effectiveness of HAART is from the 
retrospective cohort of biopsy proven HIVAN. In this study, renal survival benefit was 
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noted in 26 patients treated with antiretroviral agents compared with ten patients who did 
not receive anti-retroviral therapy. Median renal survival was significantly improved for the 
treated group compared with the untreated group (18.4 months vs. 3.9 months respectively). 
Complete viral suppression was associated with better renal outcome than partial viral 
suppression. Continuous therapy with HAART is recommended in preventing and slowing 
the progression of kidney disease due to HIVAN as evidenced by Strategies for 
Management of Antiretroviral Therapy (SMART) study. 
3.5.2 Corticosteroids 
The rationale for using corticosteroids is based on presence of significant tubulointerstitial 
inflammation seen in histology of renal biopsy of patients with HIVAN. In vitro studies 
have shown up regulation of proinflammatory genes in renal tubular cells of individuals 
with HIVAN as a possible explanation for development of tubulointerstitial disease. The use 
of corticosteroids decreases this inflammation markedly in these patients. There is 
improvement in kidney function and reduction in mean urinary protein excretion in 
patients with HIVAN with use of corticosteroids. There are no long term studies supporting 
efficiency and safety of corticosteroid use in patients with HIVAN. Most of the studies 
supporting use of corticosteroids in patients with HIVAN have been short term, non 
randomized and retrospective in design. In a single center cohort study, 20 patients with 
HIVAN were prospectively enrolled to receive treatment with corticosteroids. 17 out of 20 
patients manifested improvement in kidney function and had significant reduction in 
proteinuria.  Another study of steroid therapy employed control group and found similar 
results with no increased risk of infection in the steroid group.  Based on this evidence, 
steroids are considered as second line of therapy for patients with HIVAN especially in 
patients with a rapidly deteriorating renal function despite use of HAART. Usually a dose of 
1mg/kg (up to maximum dose of 60mg/day) with a taper over 2 months is recommended. 
Simultaneous use of HAART is essential to suppress viral replication. 
3.5.3 Inhibition of the renin-Angiotensin – Aldosterone system 
Angiotensin- Aldosterone system activation has been shown to play a role in development 
and progression of HIVAN in animal models. The rationale for the use of ACE-inhibitors in 
HIVAN is based on their favorable efficacy in most other renal glomerular diseases, 
resulting from their renal hemodynamic effect and their modulation of profibrotic cytokines 
such as transforming growth factor-beta. Two prospective studies support use of ACEI for 
the treatment of HIVAN. In a case control study of 18 patients with HIVAN prior to 
discovery of HAART, 9 were treated with captopril , and matched with 9 controls. The 
captopril treated group had improved renal survival compared with controls. Another 
prospective single center study of 34 patients with HIVAN was treated with fosinopril 
10mg/day and was compared with group of patients who refused treatment over a period 
of 5 years. The patients treated with fosinopril had better median renal survival as 
compared to untreated patients. All untreated patients progressed to ESRD over a median 
period of 5 months.  This is limited data showing efficacy of ACEI in these non randomized 
trials. There are no trials on use of angiotensin receptor blockers.  Usually ACEI may be 
used in halting the progression of HIVAN especially as first choice therapy in a patient with 
coexisting hypertension. 
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Medication used 
 
Study 
Name 
Number of patients Study Design Diagnosis of 
HIVAN 
(Biopsy 
proven or 
clinical 
diagnosis)
Outcome 
(change in renal 
function, effect 
on proteinuria) 
HAART  
Cosgrove 
23
13 patients 
received HAART 
and remaining 10 
patients received 
nothing
retrospective Clinical and 
biopsy 
proven 
HIVAN 
S/Cr stabilized 
in treated group 
as compared to 
untreated group 
HAART  
Szczech 
42 patients with 
HIVAN. 27 
patients with 
HIVAN took 
HAART 
retrospective Biopsy 
proven 
HIVAN. 
Slower 
progression to 
ESRD in 
HAART treated 
group 
Corticosteroids 
 
Eustace 21 patients of 
which 13 patients 
received steroids 
Retrospective
Systemic steroids in 
dose of 60mg for 
one month followed 
by several month 
taper 
Biopsy 
proven 
HIVAN 
Reduction in 
proteinuria and 
stabilization of 
renal function at 
3, 6, and 12 
months 
 Smith 1994 4 patients Case series of 
Systemic 
corticosteroids 
given at dose of 
60mg/day for 2-6 
weeks
Biopsy 
proven 
HIVAN 
Improvement of 
renal function 
but no effect on 
proteinuria 
 
 
 
 
Smith 1996 20 patients
Given systemic 
steroids at 
60mg/day for 2-11 
weeks followed by 
taper over 2-26 
weeks 
Prospective, no 
control group 
Clinical and 
biopsy 
diagnosis of 
HIVAN 
Improvement in 
serum creatinine 
and 
improvement in 
proteinuria. 
Serum albumin 
increased. 25% 
rate of relapse 
seen on 
withdrawl of 
steroids 
Angiotensin 
converting 
enzyme 
inhibitors 
 
 
Wei 44 patients
Fosinopril 
10mg/day was 
given for HIVAN 
Single center 
prospective with 
control group 
which received 
nothing 
Clinical and 
biopsy 
proven 
HIVAN 
Improvement of 
renal function  
with reduction 
in risk of kidney 
failure 
 Kimmel 18
9 patients treated 
with captopril 
three times daily 
and 9 patients were 
untreated 
Single center 
prospective 
Biopsy 
proven 
HIVAN 
Stabilization of 
renal function 
Table 2. Trials of Various Agents Used in Treatment of HIVAN 
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3.6 Other glomerular diseases in HIV infection 
HIV-related immune complex mediated kidney disease (HIVICK) can occur in HIV infected 
individuals of non-African descent due to deposition of or in situ development of HIV 
antigen specific immune complexes. HIV infected individuals are likely to develop non- 
HIV related kidney diseases related to various comorbidities as their age matched 
counterparts in the general population. Due to use of HAART, the aging HIV infected 
individuals with Diabetes Mellitus (DM) and Hypertension (HTN) can develop renal 
disease due to Diabetic Nephropathy or Hypertensive Nephrosclerosis. The incidence of 
diabetes mellitus, hypertension, and dyslipidemia is increased fourfold in HIV infected 
individuals on HAART as compared with HIV uninfected persons.  The treatment of CKD 
due to either DM or HTN is similar to treatment of CKD due to these co morbid conditions 
in non- HIV infected individuals.  
Hepatitis C related kidney disease can also occur in patients with HIV who are co infected 
with Hepatitis C virus. This is commonly seen in intravenous drug users. Approximately a 
third of HIV infected individuals are co infected with Hepatitis C. Membranoproliferative 
glomerulonephritis(usually with cryoglobulins) is seen on histopathology of kidney biopsy 
of the coinfected patients. These patients have circulating immune complexes of antigen- 
antibody with low complement levels and circulating cryoglobulins. They present clinically 
with proteinuria, hematuria, renal insufficiency, and maculopapular non blanching rash 
usually over the lower extremities. The treatment includes treatment of underlying 
Hepatitis C infection with interferon and Ribavarin.  
Other glomerular diseases can be seen in HIV infected individuals which includes classic 
FSGS, IgA Nephropathy, Lupus like glomerulopathy, AA amyloidosis, Membranous 
Nephropathy, and immune complex mediated Glomerulonephritis.  
 
 
Fig. 5. Membranoproliferative Glomerulonephritis in HIV patient 
It shows segmental glomerular basement duplication of Membranoproliferative 
glomerulonephritis seen in a patient coinfected with HIV and Hepatitis C. 
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Fig. 6. Nodular Diabetic Nephropathy 
It shows mesangial sclerosis consistent with Diabetic Nephropathy in an HIV infected 
patient with Diabetes Mellitus. 
 
 
Fig. 7. FSGS with Tip lesion 
It shows glomerular tip lesion of FSGS in a patient with HIV. 
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3.7 Supportive measures in chronic kidney disease 
All supportive measures need to be employed to halt the progression of renal disease in 
patients with chronic kidney disease due to HIVAN. These measures include strict blood 
pressure control especially with blockade of renin angiotensin system in proteinuric 
patients. Use of nephrotoxic agents like aminoglycosides, non-steroidal anti-inflammatory 
drugs (NSAIDs), and radiocontrast agent for computerized tomography should be 
minimized. Hyperlipidemia should be treated with lipid lowering drugs with target goal of 
low density lipoprotein level to <100mg/dl. Cessation of smoking should be emphasized. 
Complications of CKD like anemia, hyperparathyroidism should be treated accordingly to 
Dialysis Outcome Quality Initiative (DOQI) guidelines. Options for renal replacement 
therapy should be discussed with the patients and appropriate referrals made during 
chronic kidney disease stage 4. Option for renal transplantation should be discussed with 
HIV infected patients with CKD. 
4. End Stage Renal Disease (ESRD) 
End Stage Renal Disease is common in HIV infected African Americans. According to 
Unites States Renal Data System (USRDS) more than 4000 incident cases of ESRD secondary 
to AIDS Nephropathy were reported to initiate dialysis from 2000-2004. Epidemiological 
studies have characterized the marked racial differences in the ESRD incidence among HIV-
infected individuals. Blacks are the largest and fastest growing racial group with HIV in the 
United States. African Americans account for 63% of all persons with HIV infection in 
Africa. Prevalence of ESRD may rise very high in future. 
4.1 Survival of HIV infected ESRD patient 
Patients with HIV and ESRD had very high mortality rate in early 1980s before era of highly 
reactive anti-retroviral agents (HAART). These patients had advanced HIV disease with 
multiple opportunistic infections. Currently, with use of HAART, survival of HIV patients 
with ESRD has improved drastically over past decade. One year survival rate of HIV-
infected patients was equivalent to that of general population in both US and French 
database.  
All options of renal replacement therapy (RRT) should be offered to a patient who develops 
ESRD with HIV infection due to any etiology. This includes hemodialysis, peritoneal 
dialysis, and renal transplantation. Each modality of RRT has its own advantages and 
disadvantages.  
4.2 Hemodialysis 
It is the most commonly utilized modality of renal replacement therapy in HIV infected 
patients. Indications of initiation of hemodialysis are the same as in non-HIV infected 
individuals with kidney disease. Early surgical referral for placement of an arteriovenous 
fistula should be made so that a working access is available for use at time of initiation of 
chronic hemodialysis. Arteriovenous grafts (AVG) and permanent catheters are less 
favorable accesses in HIV infected individuals. AVG infection rate is high in patients with 
AIDS, asymptomatic HIV infection as compared to HIV negative patients. AVF survival 
rates are similar between HIV seropositive and HIV negative individuals with ESRD. 
Usually isolation of HIV infected patient with ESRD is not needed in dialysis unit. Reuse of 
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properly sanitized dialyzer is permissible in HIV infected ESRD individuals. There is risk of 
transmission of HIV to dialysis staff through blood and needle stick exposure. Universal 
precautions of infection control need to be observed by the dialysis staff taking care of HIV 
ESRD patients. Routine cleaning with sodium hypochlorite solution of dialysis equipment 
and commonly touched surfaces are sufficient measures with regard to treating HIV 
infected individuals on hemodialysis. There is very small removal of HIV particle during 
hemodialysis to dialysate and hence dialysate should be handled as a potentially 
contaminated body fluid.  
4.3 Peritoneal dialysis 
This modality is preferred mode of dialytic therapy due to greater independence of life 
style and preservation of residual renal function as compared to patients on hemodialysis. 
Outcome of patients between hemodialysis and peritoneal dialysis is similar and therefore 
should be offered to HIV patients with ESRD. This modality minimizes exposure of 
healthcare workers to contaminated blood and needles. Peritoneal dialysis is associated 
with increased losses of protein in the dialysate and can cause protein malnutrition. 
Peritonitis is seen in patients on peritoneal dialysis. The risk of peritonitis in HIV infected 
with ESRD is higher than the HIV negative individuals on peritoneal dialysis particularly 
peritonitis caused by pseudomonas species and fungi. HIV is eliminated in the peritoneal 
dialysate is handled as a contaminated body fluid product. Peritoneal dialysis patients are 
instructed to pour dialysate into the home toilet. They should dispose off dialysate bags 
and lines by tying them in plastic bags and disposing these bags with conventional home 
garbage. 
4.4 Kidney transplantation 
It is an available modality for RRT in HIV infected individuals with well controlled HIV 
infection. HIV RNA must be undetectable using an ultra-sensitive assay. Individual and 
graft kidney survival rates are comparable with those of other population groups.  Usually 
HIV infected individuals have high incidence of acute rejection after kidney transplantation. 
Studies have shown a 94% 3-year kidney transplant recipient survival but 67% of the 
patients in the study experienced acute rejection. The high incidence of acute rejection has 
not affected the graft survival rate due to use of immunosuppressive therapy. HIV disease 
does not progress in patients with kidney transplantation due to use of immunosuppressive 
therapy. HIV RNA levels and CD4 counts remain stable with use of immunosuppressive 
drugs. There is drug interaction of HAART with immunosuppressive drugs like 
Cyclosporin, Tacrolimus, and Sirolimus. These drugs are metabolized by cytochrome P450 
system in the liver and hence raise level of immunosuppressive drugs. Usually doses of 
immunosuppressive agents used are usually 20% of the immunosuppressive dose 
administered to renal transplant recipients without HIV because concomitant HAART tends 
to raise serum levels of Cyclosporin and Tacrolimus.  
5. Disorders of potassium 
Both hyperkalemia and hypokalemia can be seen in HIV infected individuals. 
Hyperkalemia is very common in HIV infected patients and can be due to multiple 
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causes. It can be medication induced (see Table 3) due to use of Trimethoprim/ 
Sulphamethoxazole or Pentamidine use for Pneumocytis Carinii pneumonia prophylaxis 
or treatment respectively.  
Hyperkalemia can also occur due to mineralocorticoid deficiency resulting from adrenal 
insufficiency or the syndrome of hyporenin hypoaldosteronism. Hyperkalemia can also 
occur with acute or chronic kidney disease. Usually treatment of Hyperkalemia includes 
discontinuation of any offending drug if possible, dietary potassium restriction especially in 
advanced kidney disease, and treatment of underlying cause of Hyperkalemia. 
Administration of certain medications like loop diuretics, fludrocortisones, and 
administration of corticosteroids in patients with adrenal insufficiency can be considered. 
Hypokalemia is usually seen in conditions of gastrointestinal secretory losses like vomiting, 
diarrhea or nasogastric tube drainage. It is also seen in patients with severe wasting 
syndrome in advanced HIV disease. Certain medications also can cause hypokalemia like 
diuretics, amphotericin, foscarnet, and use of anti-retroviral agents like tenofovir and 
cidofovir. Some HIV infected patients have distal tubular renal tubular acidosis and can 
present with severe hypokalemia with metabolic acidosis. 
 
PCP prophylaxis or treatment Trimethoprim/ Sulphamethoxazole 
Pentamidine 
 
Potassium sparing diuretics  
 
Amiloride or Triamterene 
Mineralocorticoid antagonists  Spironolactone and Epleronone 
Renin angiotensin blockade with angiotensin 
converting enzyme inhibitors or angiotensin 
receptor blockers 
 Captopril, Fosinopril, Lisinopril, Losartan, 
Telmisartan 
Non steroidal anti-inflammatory medications Ibuprofen, Naproxen, Indomethacin 
Immunosuppressive drugs especially in 
patients who undergo renal transplantation 
Cyclosporin, Tacrolimus 
DVT prophylaxis or treatment  Heparin( both unfractionated and low 
molecular weight heparin) 
Congestive Heart failure Digoxin 
Table 3. Drugs Causing Hyperkalemia in HIV Infected Patients 
6. Disorders of osmolality 
Hyponatremia is very common in HIV infected patients and can be seen in 30-60% of 
hospitalized patients. It is a marker of severe illness which is associated with increased 
mortality in HIV- infected patients. In one study of 212 HIV infected patients hospitalized 
patients, the mortality rate was higher in hyponatemic group as compared to patients with 
normal serum sodium (36% vs. 19%). 
Hyponatremia is usually due to multiple reasons in HIV infected patients. The commonest 
causes are volume depletion, syndrome of inappropriate antidiuretc hormone secretion 
(SIADH), and adrenal insufficiency. Volume depletion causing hyponatremia is usually due 
to gastrointestinal losses in HIV infected patients like vomiting or severe diarrhea. Volume 
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depletion is associated with low urinary sodium, high urine osmolality, increased BUN/Cr 
ratio. Hypovolemia usually responds well to intravenous hydration, along with measures to 
treat the underlying cause of volume losses. Syndrome of inappropriate antidiuretic 
hormone secretion can occur due to variety of intrapulmonary or intracranial causes like 
pneumocystis carini pneumonia, pulmonary tuberculosis, cerebral toxoplasmosis, and 
histoplasmosis etc. SIADH is treated with free water restriction and treatment of underlying 
infection or malignancy. In some cases, one may have to use specific medications to treat 
SIADH like demeclocycine or ADH receptor antagonists like conivaptan.  
Adrenal insufficiency is an uncommon cause of hyponatremia as compared to hypovolemia 
and SIADH. Hyponatremia results from cortisol deficiency leading to urinary salt wasting.  
The adrenal insufficiency can result from adrenalitis, an abnormality that may be infectious 
in etiology caused by cytomegalovirus, mycobacterium avium intracellulare, or HIV itself. 
Adrenal hemorrhage and infiltration with Kaposi’s sarcoma may also be seen.  
Hypernatremia is seen uncommonly and results from loss of water from the body in excess 
of salt. This is seen usually in HIV infected patients admitted to the hospital due to 
opportunistic infections accompanied by high fevers. It occasionally can occur as 
consequence of loss of massive amounts of water in the urine due to development of 
Diabetes Insipidus or adipsia. 
7. Disorders of acid-base disturbances 
Acid base disturbances in HIV infected patients are commonly caused by infections or 
drugs. Both metabolic and respiratory acid base disorders are encountered in HIV infected 
patients. Respiratory alkalosis and respiratory acidosis may occur in opportunistic infections 
of the lungs or central nervous system. Metabolic acidosis can be of both anion and 
nonanion type. Nonanion gap metabolic acidosis can occur as a result of several different 
processes taking place in the body. These include gastrointestinal losses due to diarrhea, 
renal acid loss due to adrenal insufficiency or syndrome of hyporeninemic 
hypoaldosteronism, or nephrotoxicity of the drugs used to treat HIV infected patients.  
High anion gap metabolic acidosis in HIV infected patients occur due to multiple causes. 
These patients are prone to multiple opportunistic infections especially in untreated HIV 
individuals which can be serious and can result in sepsis induced lactic acidosis (type A 
lactic acidosis). Type B lactic acidosis can result from mitochondrial dysfunction in the 
absence of sepsis, hypoperfusion or hypoxia. Type B Lactic Acidosis has been reported with 
use of nucleoside reverse transcriptase inhibitors like zidovudine, didanosine, zalcitabine, 
and stavudine. Life threatening lactic acidosis is rare; 5-25% of HAART treated patients may 
develop mildly elevated lactate levels without acidosis. It is not recommended to screen HIV 
positive patients for presence of lactic acidosis, but lactic acid level should be measured in 
patients who present with low bicarbonate level, an elevated anion gap, or abnormal liver 
enzymes. 
8. Disorders of calcium 
Both hypercalcemia and hypocalcemia can be seen in patients infected with HIV. It is 
present in 6.5% of HIV infected patients. Hypocalcemia is usually due to presence of 
vitamin D deficiency, pancreatitis, hypoparathyroidism, use of certain drugs like foscarnet, 
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tenofovir, pentamidine for treatment of pneumocystis carinii pneumonia. Hypomagnesemia 
can accompany hypocalcemia in these patients. 
Hypercalcemia can occur due to use of certain drugs like high doses of vitamin D and 
calcium supplements. Certain diseases like pulmonary tuberculosis, sarcoidosis, 
Mycobactrium avium intracellulare infection, Hyperparathyroidism, monoclonal 
gammopathy, human T lymphotropic virus (HTLV-1) associated Lymphoma, and other 
malignancies have been associated with hypercalcemia in HIV infected individuals. 
Hypercalcemia can be severe in HTLV -1 associated lymphoma which needs urgent 
treatment. Hypercalcemia may be associated with kidney failure due to its vasoconstrictive 
effects which is often reversible. Hypercalcemia is managed usually with IV hydration 
followed by forced diuresis, calcitonin, and bisphosphonates. Hemodialysis against low 
calcium bath may be needed in patients presenting with severe hypercalcemia with CNS 
manifestations. 
9. Disorders of magnesium 
Hypomagnesemia is encountered frequently in HIV infected individuals. It usually results 
from the use of certain medications like foscarnet or pentamidine especially if both are used 
together. Hypomagnesemia has been associated with nonrecovery of renal function and 
high inpatient mortality in AIDS patients with acute kidney injury.  
10. Disorders of phosphate 
Hypophosphatemia is seen usually as a result of drug therapy in HIV infected patients. The 
drugs usually involved with hypophosphatemia are tenofovir, foscarnet and other 
antiretroviral agents. Hypophosphatemia results from fanconi’s syndrome in these patients 
which cause phosphaturia and hence hypophosphatemia.  
Hyperphosphatemia is seen usually in patients who develop chronic kidney disease due to 
HIV related or non-HIV related causes. It is usually seen in advanced stages of chronic 
kidney disease usually stage 4 &5. The management of hyperphosphatemia includes dietary 
phosphate restriction, use of non calcium based phosphate binders etc. 
Hyperparathryroidism resulting from chronic kidney disease is managed on the same 
principles as in non-HIVrelated CKD. 
11. Nephrotoxicity of anti-retroviral agents 
Nephrotoxicity is commonly encountered with use of anti-retroviral medications used for 
treatment of HIV infected individuals. Kidneys are involved in the excretion of these 
drugs and hence are exposed to high concentrations of these drugs, their metabolites or 
both. These medications require dose adjustment in patients with reduced GFR. Drug 
induced nephrotoxicity is seen in clinical practice and accounts for 2-15% cases of acute 
kidney injury (AKI). The exact frequency of nephrotoxicity induced by anti-retroviral 
agents in HIV infected patients is unknown. The dose recommendations by the 
pharmaceutical manufacturers are based on creatinine clearance and clinical validity of 
Modification of Diet in Renal Disease (MDRD) and Cockroft-Gault equations in HIV 
patients is not available. A brief overview of commonly used groups of drugs is given 
below. 
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11.1 PI (Protease Inhibitors) 
Protease inhibitors are metabolized primarily in the liver. Urinary excretion accounts for 
approximately 10% of parent drug clearance for indinavir and 5% or less for other drugs in 
this class. PI’s are highly protein bound (60-90%) and have large volume of distribution. 
None of the currently available PI requires dose adjustment for patients with reduced GFR. 
These medications are not cleared significantly by dialysis (both hemodialysis and 
peritoneal dialysis) although studies supporting this evidence recruited small number of 
patients. Some of the commonly used protease inhibitors are given in Table 4. 
No adjustment of dose is needed in patients with reduced GFR or on dialysis. 
 
Brand Name Generic Name Normal Dose
crixivan Indinavir 800mg q8hour
Invirase Saquinavir 1000mg bid with ritonavir 100mg bid 
Norvir Ritonavir 600mg bid
Viracept Nelfinavir 750mg tid
Kaletra Lopinavir/Ritonavir Lopinavir 400mg/ritonavir 100mg bid 
Reyatas Atazanavir 1400mg bid
Lexiva Fos-amprenavir 1400mg bid
Fortovase Saquinavir( soft gel) 1200mg tid
Table 4. Commonly Used Protease Inhibitors with Doses in HIV 
11.2 NRTI (Nucleoside /Nucleotide Reverse Transcriptase Inhibitors) 
These drugs are eliminated by the kidney except abacavir which is mostly metabolized by 
the liver (Table 5 & 6). Urinary excretion ranges from 20-70% for various formulations 
except abacavir which is eliminated by 1% through the kidney. All the agents need dose  
 
Brand Name Generic Name Normal Dose Dose Adjustment Needed for 
Reduced GFR  
Emtriva Emtricitabine 200mg qd Dose interval needs to be 
increased depending on GFR 
Epivir Lamivudine 150mg bid or 
300mg /day 
Dose needs to be decreased based 
on level of GFR 
Hivid Zalcitabine 0.75mg tid Dose interval needs to be 
increased based on GFR 
Retrovir Zidovudine 300mg bid or 
200mg tid 
Dose needs to be decreased in 
dialysis patients 
Videx Didanosine ≥60kg: 200mg bid
≤ 60kg:125mg bid
Dose needs to be reduced in 
patients with compromised GFR 
Viread Tenofovir 300mg /day Dose interval needs to be 
increased in patients with 
reduced GFR 
Ziagen abacavir 300mg bid No dosage adjustment needed 
Zerit Stavudine ≥60kg:40mg q12h
≤60kg:30mg q12h
Dose needs to be reduced in 
patients with reduced GFR 
Table 5. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors Dosing in Patients with 
Normal and Impaired Renal Function 
www.intechopen.com
 Kidney Involvement in HIV Infection  
 
109 
adjustment except abacavir in patients with reduced GFR. In dialysis patients, these drugs 
should be given after dialysis session. Unlike PI, these drugs have low protein binding 
and small volume of distribution. These drugs are eliminated by both glomerular 
filtration and tubular secretion. Nucleoside RTIs are less nephrotoxic than Nucleotide 
RTIs. 
Other drugs such as Cimetidine and Trimethoprim can reduce their elimination by 
competing for tubular secretion by organic cation pathway.  
Fixed drug combination should be avoided in patients with GFR <50ml/min. The reader 
should refer to individual package inserts for guidance with dosing of antiretroviral 
combinations. 
 
Brand Name Generic Name Usual Dose 
Combivir Lamivudine/ Zidovudine One tablet bid 
Trizivir Abacavir, Lamivudine, Zidovudine One tablet bid 
Truvada Emtricitabine, Tenofovir One tablet daily 
Epzicom Abacavir, Lamivudine One tablet daily 
Table 6. Nucleoside Reverse Transcriptase Inhibitors Fixed Dose Combinations 
11.3 NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitors) 
These drugs are eliminated primarily by the liver. These drugs are protein bound and they 
do not require drug adjustment in patients with reduced GFR. These drugs are removed to 
some extent by dialysis and should be dosed after hemodialysis. Nevirapine is removed 
significantly by peritoneal dialysis but it remains unclear if a dosage adjustment is needed 
for patients on peritoneal dialysis as its trough plasma level remains unaffected. 
Efavorenz and Delavirdine have not been studied in patients with reduced GFR or on 
dialysis. 
11.4 Pathogenesis of nephrotoxicity 
Nephrotoxicity results from mitochondrial dysfunction induced by NRTIs since they 
inhibit nuclear or mitochondrial DNA polymerase from host cell along with inhibition of 
reverse transcriptase of HIV. NRTIs affects DNA polymerase of mitochondria with 
subsequent deficits in mitochondrial DNA encoded enzymes of the mitochondrial 
respiratory chain. Oxidative phosphorylation is disrupted with deficits in energy 
production. This leads to production of lactate from anaerobic respiration which results in 
clinical effects like lactic acidosis, cardiomyopathy, peripheral neuropathy, fatty liver, and 
pancreatitis. Clinically it manifests as tubular injury to proximal tubular cells. 
Histologically is characterized by tubulointerstitial nephropathy with mitochondrial 
cytopathy. Protease inhibitors induce kidney injury by causing crystalluria, renal stones, 
and tubulointerstitial disease.  
11.5 Renal manifestations of toxicity of antiretroviral agents 
Various lesions caused by anti-retroviral agents as cause of AKI are acute tubular necrosis 
(ATN), crystalluria, Fanconi’s syndrome, distal tubular acidosis (RTA), nephrogenic 
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diabetes insipidus (NDI), and lactic acidosis. Chronic kidney disease can also result from 
long term HAART use. 
AKI secondary to acute tubular necrosis (ATN) is commonly seen in patients with 
HIVinfection(up to 10%) and regarding HAART, tenofovir and indinavir are most 
commonly associated with nephrotoxicity.  
Tenofovir is taken up into renal epithelial cells by basolateral membrane human organic 
anion transporters, then secreted into the urine across the apical membrane by 
transporters called multidrug resistance associated protein. Tenofovir toxicity was first 
reported by Verhelst et al in 2002. Tenofovir is associated with reversible Fanconi’s 
syndrome, nephrogenic diabetes insipidus and they occur within 5-12 months after 
starting therapy with tenofovir. These abnormalities resolve within few months of 
discontinuation of tenofovir. Renal biopsy reveals cytoplasmic vacuolization, apical 
localization of nuclei, and reduction of brush border on proximal tubular cells. Clinically, 
it is manifested by glucosuria, aminoaciduria, hyperuricosuria, hypouricemia and 
hypophosphatemia due to phosphaturia. Most patients who develop tenofovir related 
renal dysfunction also have concomitant use of ritonavir. Patients taking tenofovir should 
have close monitoring of renal function especially if ritonavir is used concomitantly. 
Glucosuria and hypophosphatemia are early manifestations of tenofovir induced injury 
and tenofovir should be discontinued promptly. Nephrotoxicity improves upon 
discontinuation of tenofovir in most cases although in some patients serum creatinine 
levels remain above baseline levels. 
Indinavir has been associated with crystalluria, nephrolithiasis, and obstructive 
nephropathy which can occur anytime after initiation of drug and has been reported in as 
many as 33% of patients on chronic therapy. Obstructive nephropathy may be mild to 
severe and may need urologic intervention. It is recommended to monitor patients on 
indinavir periodically during the first 6 months of therapy and then biannually. The use of 
indinavir has declined recently in patients with HIV.  
Renal calculi have been reported with use of nelfinavir and saquinavir. Ritonavir has been 
associated with AKI in few reports.  Atazanavir can induce AKI secondary to interstitial 
nephritis.  
Some NRTI can induce interstitial nephritis and proximal tubular dysfunction like abacavir. 
Fanconi’s syndrome has also been reported in patients using DDI and 
stavudine/lamivudine.  
Lactic Acidosis has been described with use of NRTI. The development of lactic acidosis can 
range from asymptomatic chronic hyperlactemia to acute life threatening lactic acidosis. 
Lactic acidosis was first described with didanosine and zidovudine. It is believed to be 
caused by inhibition of mitochondrial DNA polymerase by intracellularly generated 
triphosphate metabolites of these drugs. Approximately 20-30% of patients who are treated 
with these drugs can be found to have asymptomatic hyperlactemia that develops several 
months after institution of therapy. Severe lactic acidosis (lactate acid level >5mmol/L) is 
clinically characterized by fatigue, nausea, vomiting, anorexia, and abdominal pain is rare 
and is associated with 80% mortality rate. Risk factors associated with lactic acidosis include 
longer duration of treatment with HAART, older age, female, pregnancy, 
hypertriglyceridemia, impaired renal function, and use of alcohol. Most patients with 
asymptomatic hyperlactemia remain stable. Stavudine and didanosine (alone or in 
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combination) have been associated with hyperlactinemia and lactic acidosis, although all of 
NRTI have been implicated. Routine monitoring of lactic acid is not recommended except in 
patients with symptoms of lactic acidosis.  
NNRTI can rarely be associated with AKI in association with rash and eosinophilia. 
HAART treated patients may develop chronic kidney disease especially in patients with 
partial recovery of renal function after an episode of AKI. These medications are excreted 
through kidneys and may be involved in causation of chronic kidney disease in HIV 
patients.  
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